Amgen's Q3 2016 earnings call highlighted strong operating leverage, with earnings growth exceeding revenue growth.  Management's guidance was upgraded, reflecting continued confidence in the company's strategy and strong performance.  Positive data from various product development pipelines,  particularly in oncology and cardiovascular, suggest continued positive momentum in the near future.

[2]
